SYRE stock forecast, quote, news & analysis
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases... Show more
Why Spyre Therapeutics (SYRE) Is Up +66% in the Last 30 Days
Key Takeaways
- SYRE stock surged +66% over the past 30 days, driven primarily by positive Phase 2 SKYLINE trial data for SPY001 and a successful $463.5 million public offering.
- Over the past quarter, shares climbed +115%, reflecting sustained clinical progress and favorable analyst sentiment in the biotechnology sector.
- Key catalysts include SPY001 induction results in ulcerative colitis patients and upsized equity financing to advance the IBD (inflammatory bowel disease) pipeline.
- Biotech market trends and institutional interest amplified the upward price movement amid positive trial outcomes.
Spyre Therapeutics (SYRE) Company Overview and Market Position
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapeutics for inflammatory bowel disease (IBD) and other immune-mediated conditions. Its pipeline features extended half-life antibodies targeting key pathways, including SPY001 (an anti-α4β7 monoclonal antibody (mAb) for ulcerative colitis and Crohn's disease), SPY002 and SPY072 (anti-TL1A (tumor necrosis factor-like ligand 1A) mAbs), and SPY003 (anti-IL-23 (interleukin 23) mAb), along with combination therapies like SPY120. The company's business model emphasizes antibody engineering, dose optimization, and rational combinations to improve efficacy in IBD treatments. In the competitive biotech landscape for gastroenterology, Spyre differentiates through its targeted integrin, TL1A, and IL-23 programs, positioning it to address unmet needs in a market dominated by established therapies. Strong clinical data and funding have bolstered its fundamentals, directly fueling recent stock price gains amid biotech sector volatility.
Spyre Therapeutics (SYRE) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, SYRE stock rose from a closing price of $43.06 to $71.39, marking a +66% increase. The movement was volatile and trend-driven, with sharp gains following key announcements, punctuated by brief pullbacks.
In the past quarter, shares advanced from $33.24 to $71.39, delivering a +115% gain. Performance was steadily upward overall, though with fluctuations tied to news flow, including elevated volume during recent events. This aligns with broader biotech market trends, where positive clinical readouts propelled investor interest in SYRE's stock price.
What Drove SYRE Stock Price in the Last 30 Days
The primary catalyst was Spyre's April 13, 2026, announcement of potential best-in-class Part A induction results from the SKYLINE Phase 2 trial of SPY001 in moderate-to-severe ulcerative colitis patients, sparking a rapid rally. This data highlighted strong efficacy, boosting market sentiment around the company's lead IBD asset. Concurrently, Spyre launched a proposed $300 million public offering on the same day, which was upsized and priced at $62 per share for $403 million on April 14, closing at $463.5 million on April 16 with the full exercise of underwriters' options. The successful fundraising signaled confidence in the pipeline, driving shares up over 25% in a single session amid high volume. These events overshadowed minor dips, with biotech sector enthusiasm and analyst optimism amplifying the stock price surge.
What Drove SYRE Stock Performance Over the Last Quarter
The quarter's +115% advance built on cumulative clinical momentum, including February priorities for proof-of-concept readouts across the pipeline. Positive developments in SPY001 and combination assets sustained upward pressure, supported by a February earnings report where EPS of -$0.74 beat estimates, reflecting efficient cash burn despite no revenue typical for clinical-stage biotechs. Analyst upgrades and a consensus Strong Buy rating with targets around $57 further fueled gains. Macro factors like improving biotech funding environments and IBD market demand contributed, with institutional buying evident in volume spikes. The recent trial data and financing represented the strongest impacts, cementing the quarter's robust stock analysis.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top-performing AI trading bots from its extensive library of hundreds of algorithms actively trading thousands of tickers across various markets. These curated bots are selected based on recent performance metrics, relevance to current market trends, and strategy diversity, including momentum, mean reversion, and pattern recognition approaches over short-term, swing, or long-term timeframes. Users can explore detailed backtested results, live performance, and risk-adjusted returns to identify bots suited to their trading style. For investors seeking data-driven stock analysis and automated market trends insights, reviewing these trending robots offers a valuable starting point.
SYRE Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor upcoming proof-of-concept data readouts for SPY001 and other pipeline assets, including combination therapies like SPY120 and SPY130. Further SKYLINE trial updates and potential Phase 3 initiations will be critical. Next quarterly earnings will provide cash runway visibility post-financing. Broader IBD industry trends, such as competitor advancements and regulatory changes, could influence sentiment. Macroeconomic factors like interest rates and biotech M&A (mergers and acquisitions) activity remain key, alongside risks from clinical setbacks or dilution. Strategic partnerships or additional funding rounds bear watching for pipeline acceleration.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
SYRE's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for SYRE turned positive on June 11, 2026. Looking at past instances where SYRE's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 09, 2026. You may want to consider a long position or call options on SYRE as a result. In of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SYRE advanced for three days, in of 293 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 166 cases where SYRE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYRE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
SYRE broke above its upper Bollinger Band on June 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SYRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.903) is normal, around the industry mean (20.059). P/E Ratio (1.716) is within average values for comparable stocks, (35.871). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.677). SYRE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (526.316) is also within normal values, averaging (361.315).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company
Industry Biotechnology